Evidence map›Paper›PMID 29058166›Full record

ArticleInternational urology and nephrology2018

Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.

Tomasz W Kaminski, Krystyna Pawlak, Malgorzata Karbowska, Michal Mysliwiec, Waldemar Grzegorzewski, Jakub Kuna, Dariusz Pawlak

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. The Association ofMicroorganisms · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Chronic kidney disease in the pathogenesis of acute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tomasz W KaminskiDepartment of Pharmacodynamics, Medical University of Bialystok, 2C Mickiewicza Str., 15-089, Białystok, Poland. tomasz.kaminski@umb.edu.pl.
Krystyna PawlakDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Białystok, Poland.
Malgorzata KarbowskaDepartment of Pharmacodynamics, Medical University of Bialystok, 2C Mickiewicza Str., 15-089, Białystok, Poland.
Michal MysliwiecDepartment of Nephrology and Clinical Transplantation, Medical University of Bialystok, Białystok, Poland.
Waldemar GrzegorzewskiDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland.
Jakub KunaDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland.
Dariusz PawlakDepartment of Pharmacodynamics, Medical University of Bialystok, 2C Mickiewicza Str., 15-089, Białystok, Poland.
Medical University of Białystok · PLUniversity of Warmia and Mazury in Olsztyn · PL

Funding

Krajowy Naukowy Osrodek Wiodacy 116/KNOW/15Uniwersytet Medyczny w Bialymstoku N/ST/MN/17/001/2211Uniwersytet Medyczny w Bialymstoku N/ST/MN/17/003/2211
6 · The paper itself

Abstract

purposeChronic kidney disease (CKD) is an estimated risk factor for increased mortality and morbidity due to fibrinolytic system disturbances. Progressive loss of renal function leads to retention of uremic toxins. Anthranilic acid (AA) is a tryptophan-derived uremic toxin with multidirectional properties that can affect the hemostatic system. The goal of this study was to examine the association between AA and the parameters of fibrinolysis at different stages of CKD.

methodsPatients with CKD were divided into two groups: mild-to-moderate (n = 20) and severe-to-end-stage CKD (n = 28). Seventeen healthy volunteers served as an additional control group. Parameters of fibrinolysis, inflammation, and monocytes activation were determined by ELISA immune-enzymatic kits. AA levels were evaluated using high-performance liquid chromatography.

resultsAA concentration and parameters of fibrinolysis: urokinase-type plasminogen activator (uPA), its soluble receptor (suPAR), tissue plasminogen activator (tPA), tissue plasminogen activator inhibitor-1 (PAI-1) and plasmin-antiplasmin complex (PAP) were significantly elevated in the CKD groups compared with the controls. The markers of inflammation, monocyte activation, and impaired kidney function were also increased in those with CKD. AA was positively correlated with the uPA/suPAR system in the early stages of CKD, whereas during severe-to-end-stage CKD, inverse relationships were observed between AA, tPA and PAI-1. Additionally, AA was an independent variable associated with tPA in patients with CKD overall and with uPA levels in the mild-to-moderate CKD group.

conclusionsObtained results suggest for the first time the association between AA and the fibrinolytic system in CKD patients. The distinct relationship between AA and individual parameters of fibrinolysis appears to be dependent on CKD stage.

Indexed as

FibrinolysisAdultAgedalpha-2-AntiplasminBiomarkersCase-Control StudiesFemaleFibrinolysinHumansInflammationKidney Failure, ChronicMaleMiddle AgedMonocytesortho-AminobenzoatesPlasminogen Activator Inhibitor 1alpha-2-Antiplasminanthranilic acidBiomarkersFibrinolysinortho-AminobenzoatesPlasminogen Activator Inhibitor 1plasmin-plasmin inhibitor complexReceptors, Urokinase Plasminogen ActivatorSERPINE1 protein, humanTissue Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorAnthranilic acidFibrinolysisFibrinolytic capacityHemostasisRenal failure

Identifiers

PMID29058166
PMCPMC5758659
OpenAlexW2766227186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.